DOP2013000074A - Derivados de 1,4-oxazepano - Google Patents

Derivados de 1,4-oxazepano

Info

Publication number
DOP2013000074A
DOP2013000074A DO2013000074A DO2013000074A DOP2013000074A DO P2013000074 A DOP2013000074 A DO P2013000074A DO 2013000074 A DO2013000074 A DO 2013000074A DO 2013000074 A DO2013000074 A DO 2013000074A DO P2013000074 A DOP2013000074 A DO P2013000074A
Authority
DO
Dominican Republic
Prior art keywords
ring
oxazepano
derivatives
optionally substituted
membered aromatic
Prior art date
Application number
DO2013000074A
Other languages
English (en)
Inventor
Ikuo Fujimori
Tetsuya Tsukamoto
Yuji Ishichi
Masami Yamada
Taku Kamei
Yoshihisa Nakada
Tomoya Yukawa
Nobuki Sakauchi
Yusuke Ohba
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000074(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2013000074A publication Critical patent/DOP2013000074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un compuesto que tiene una actividad inhibidora de la recaptación de monoamina, que está representado por la fórmula (I) en donde el anillo A es un anillo aromático de 6 miembros opcionalmente sustituido, el anillo B es Los sustituyentes en el anillo A se unen opcionalmente para formar, junto con el anillo A, un anillo fusionado aromático de 9 ó 10 miembros opcionalmente sustituido y los demás símbolos son como se definen en la descripción o una de sus sales.
DO2013000074A 2010-10-07 2013-04-04 Derivados de 1,4-oxazepano DOP2013000074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010227864 2010-10-07
JP2011175336 2011-08-10

Publications (1)

Publication Number Publication Date
DOP2013000074A true DOP2013000074A (es) 2014-07-31

Family

ID=44906302

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000074A DOP2013000074A (es) 2010-10-07 2013-04-04 Derivados de 1,4-oxazepano

Country Status (26)

Country Link
US (2) US8722662B2 (es)
EP (1) EP2625170A1 (es)
JP (1) JP5873487B2 (es)
KR (1) KR20130116073A (es)
CN (1) CN103261176B (es)
AR (1) AR083313A1 (es)
AU (1) AU2011313150A1 (es)
BR (1) BR112013008420A2 (es)
CA (1) CA2813911A1 (es)
CL (1) CL2013000927A1 (es)
CO (1) CO6700872A2 (es)
CR (1) CR20130158A (es)
DO (1) DOP2013000074A (es)
EA (1) EA201390491A1 (es)
EC (1) ECSP13012593A (es)
GE (1) GEP20156295B (es)
IL (1) IL225189A0 (es)
MX (1) MX2013003749A (es)
NZ (1) NZ608499A (es)
PE (1) PE20140239A1 (es)
PH (1) PH12013500657A1 (es)
SG (1) SG188346A1 (es)
TW (1) TW201242956A (es)
UY (1) UY33650A (es)
WO (1) WO2012046882A1 (es)
ZA (1) ZA201302112B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013093484A1 (en) * 2011-12-21 2013-06-27 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
US9475809B2 (en) * 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
CN105693652B (zh) * 2014-11-27 2019-01-08 常州合全药业有限公司 一种4-叔丁基-5-乙基-6-氧亚基-1,4-噁吖庚环-4,5-二甲酸基酯的合成方法
WO2016093285A1 (ja) 2014-12-10 2016-06-16 小野薬品工業株式会社 ジヒドロインドリジノン誘導体
JP2018516887A (ja) 2015-05-08 2018-06-28 ヴァーテラス ホールディングス エルエルシー カルボキサミドをチオカルボキサミドに変換するための方法
WO2024251807A1 (en) * 2023-06-08 2024-12-12 Cybin Irl Limited Companion animal treatments
JP2026525234A (ja) * 2023-06-27 2026-07-29 ライカルマ・セラピューティクス，インコーポレーテッド リアノジン受容体が関与する障害を処置するための作用剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3018222A (en) 1956-08-28 1962-01-23 Ravensberg G M B H Central stimulant and appetite depressant composition
US4010166A (en) 1974-11-25 1977-03-01 Ciba-Geigy Corporation 1,4-Oxazepines
DE3242923A1 (de) 1982-11-20 1984-05-24 Basf Ag, 6700 Ludwigshafen 7-phenyl-7-phenoxymethyl-hexahydro-1,4-oxazepine, ihre herstellung und verwendung
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
ZA971525B (en) 1996-02-22 1997-10-21 Neurosearch As Tropane derivatives, their preparation and use.
EP1586584A1 (en) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
EP1324993A2 (en) 2000-04-18 2003-07-09 Cytovia, Inc. Substituted 1,4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
GB0229743D0 (en) * 2002-12-20 2003-01-29 Arakis Ltd Novel benzoxazocines
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
BRPI0618011A2 (pt) 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
US20090054398A1 (en) 2006-03-10 2009-02-26 Astrazeneca Ab Chemical compounds
AU2007267182A1 (en) 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Benzazepine derivatives as monoamine reuptake inhibitors
EA200970510A1 (ru) 2006-11-24 2009-12-30 Такеда Фармасьютикал Компани Лимитед Гетеромоноциклическое соединение и его применение
GB0721178D0 (en) 2007-10-29 2007-12-05 Glaxo Group Ltd Chemical compounds
WO2009119528A1 (ja) 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
WO2010016554A1 (ja) 2008-08-07 2010-02-11 武田薬品工業株式会社 環状アミン化合物

Also Published As

Publication number Publication date
JP2013538786A (ja) 2013-10-17
UY33650A (es) 2012-04-30
ZA201302112B (en) 2013-12-23
WO2012046882A1 (en) 2012-04-12
JP5873487B2 (ja) 2016-03-01
CL2013000927A1 (es) 2013-09-13
EA201390491A1 (ru) 2013-11-29
US20130267494A1 (en) 2013-10-10
US20120088748A1 (en) 2012-04-12
AU2011313150A1 (en) 2013-04-18
PH12013500657A1 (en) 2013-05-06
MX2013003749A (es) 2013-05-09
EP2625170A1 (en) 2013-08-14
ECSP13012593A (es) 2013-07-31
NZ608499A (en) 2015-03-27
PE20140239A1 (es) 2014-03-07
US8722662B2 (en) 2014-05-13
CN103261176B (zh) 2015-06-03
CN103261176A (zh) 2013-08-21
GEP20156295B (en) 2015-06-10
BR112013008420A2 (pt) 2016-06-28
CO6700872A2 (es) 2013-06-28
AR083313A1 (es) 2013-02-13
KR20130116073A (ko) 2013-10-22
IL225189A0 (en) 2013-06-27
TW201242956A (en) 2012-11-01
SG188346A1 (en) 2013-04-30
CA2813911A1 (en) 2012-04-12
CR20130158A (es) 2013-05-03

Similar Documents

Publication Publication Date Title
ECSP13012593A (es) Derivados de 1,4-oxazepano
CR20160296A (es) Benzamidas sustituidas y métodos para usarlas
CL2017001533A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
CR20140218A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas iii
MX2020005498A (es) Inhibidores de cdk.
CR20140450A (es) Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso
GT201400195A (es) Compuestos de heterociclilo como inhibidores de mek
CO2017000332A2 (es) Coŵpuestos heterocíclicos como receptores huérfanos relacionados con retinoide gamma-t (ror γt)
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
CR20150061A (es) Compuesto de pirazolopirimidinas
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
CY1118950T1 (el) Νεα παραγωγα πυραζολιου
UY4153Q (es) Batería
CR20150440A (es) Nuevos derivados de piridina
CR20140195A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas
CR20160459A (es) Nuevos derivados de piridina
MX2017007377A (es) Compuestos organicos.
CO6491037A2 (es) Derivados de pirazinooxazepina
CL2015002697A1 (es) Buje de abertura ascendente y montaje de cabezal de barril central que comprende el mismo.
BR112019014963A8 (pt) Compostos-bis para dispositivos opticamente ativos
MX2013012982A (es) Metodo para promover el crecimiento de plantas.
CR20160448A (es) Nuevos derivados de piridina
ECSP13012535A (es) Compuesto heterocíclico y sus usos